ANGO News 14.36 Angiodynamics (ANGO)

New Post Public Reply Private Reply Replies (0) Message Board

Apr 17, 2014 at 5:39 PM

Angiodynamics (ANGO) 14.36 $ANGO

Weakness Seen in AngioDynamics (ANGO): Stock Tumbles 7.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Apr 14, 7:43AM CDT
AngioDynamics falls 7.8% last trading session, continuing the downtrend

AngioDynamics Q3 Earnings Flat but Beat Ests - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 8:28AM CDT
ANGO lowered its adjusted EPS guidance for fiscal 2014 to a range of 60 to 63 cents from the prior range of 63 to 67 cents.

AngioDynamics Reports Fiscal 2014 Third Quarter Financial Results
GlobeNewswire - Wed Apr 09, 3:01PM CDT
-- Net sales increase 8% over prior year to $88.2 million

AngioDynamics to Report Fiscal 2014 Third Quarter Financial Results
GlobeNewswire - Tue Mar 25, 5:30AM CDT
AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced it will report its fiscal 2014 third quarter financial results for the period ended February 28, 2014, on Wednesday, April 9, 2014, after the close of the U.S. financial markets.

AngioDynamics Awarded $74.9 Million in Case Against biolitec AG
GlobeNewswire - Thu Mar 20, 5:30AM CDT
AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced a recent court action in its legal case against biolitec AG.

FDA Expands Angiovac Clearance for AngioDynamics - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 17, 10:42AM CDT
The expanded clearance for AngioVac cannula seems reasonable given the wide acceptance of the product across the U.S.

AngioDynamics Raised to Hold - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 14, 11:00AM CDT
A promising guidance, an innovative pipeline and management's efforts to leverage operational activities represent a potential upside for AngioDynamics going forward.

AngioDynamics (ANGO) in Focus: Stock Moves 5.7% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 13, 8:18AM CDT
AngioDynamics Inc. (ANGO) was a big mover last session, as the company saw its shares rise by roughly 6% on the day.

Wednesday's Top Upgrades (and Downgrades)
Rich Smith, The Motley Fool - Motley Fool - Wed Mar 12, 11:00AM CDT
This series, brought to you by Yahoo! Finance, looks at which upgrades and downgrades make sense, and which ones investors should act on. Today, our headlines feature downgrades for clothiers Urban Outfitters and American Eagle Outfitters . But...

Upgrade Alert for Angiodynamics (ANGO)
Comtex SmarTrend(R) - Wed Mar 12, 7:05AM CDT
Angiodynamics (NASDAQ:ANGO) was upgraded from Market Perform to Outperform at Raymond James today. The stock closed yesterday at $15.85 on volume of 175,000 shares, above average daily volume of 146,000. AngioDynamics, Inc. designs, develops, manufactures, and markets therapeutic and diagnostic devices. The Company's products enable interventional physicians to treat peripheral vascular disease and other non-coronary diseases. AngioDynamic's product lines consist of angiographic catheters, hemodialysis catheters, image guided vascular access products, and thrombolytic products.

AngioDynamics Receives Expanded FDA Clearance for AngioVac
GlobeNewswire - Tue Mar 11, 5:30AM CDT
AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced the U.S. Food and Drug Administration (FDA) cleared an expanded indication for its AngioVac cannula for venous drainage during extracorporeal bypass for up to six hours to include removal of fresh, soft thrombi or emboli.

AngioDynamics Gets 3rd FDA Approval for BioFlo - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 4:30PM CDT
The commercial launch of the catheter, which is expected in the fourth quarter of fiscal year 2014, is likely to boost ANGO's 15% share in the $100 million chronic dialysis catheter market.

AngioDynamics Receives FDA Clearance for DuraMax Dialysis Catheter With BioFlo Technology to Reduce Catheter-Related Thrombus
GlobeNewswire - Fri Mar 07, 5:30AM CST
AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced the U.S. Food and Drug Administration granted 510(k) clearance for its BioFlo DuraMax chronic hemodialysis catheter.

AngioDynamics Updates U.S. Tip Location Strategy
GlobeNewswire - Fri Mar 07, 2:59AM CST
AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced the U.S. Food and Drug Administration (FDA) rejected its distribution partner, Medcomp Inc.'s, 510(k) application for the Celerity tip location system.

Coverage on Covance Initiated - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 2:20PM CST
On Mar 06, 2014, we initiated coverage on Covance.

Cyberonics Upped to Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 2:10PM CST
On Feb 26, 2014, Zacks Investment Research upgraded Cyberonics Inc. to a Zacks Rank #2 (Buy).

AngioDynamics to Present at the Barclays Global Healthcare Conference
GlobeNewswire - Mon Mar 03, 6:00AM CST
AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today that Joseph M. DeVivo, President and Chief Executive Officer, is scheduled to address the Barclays Global Healthcare Conference on Tuesday, March 11, 2014, at 4:15 p.m. ET. The conference will be held at the Loews Hotel in Miami, Fla.

BioScrip Down on Q4 Loss, Poor Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 10:30AM CST
BioScrip recently declared its fourth-quarter 2013 results.

Fresenius Medical Care Beats on Q4 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 27, 9:20AM CST
For full-year 2013, FMS reported a 6.5% fall in net earnings to $1.1 billion and a 6% drop in net earnings per share to $1.83.

Q4 Earnings Beat at AmSurg, Poor Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 26, 9:10AM CST
AmSurg Corp.'s fourth-quarter 2013 EPS from continuing operations climbed 22% year over year to 60 cents.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Perk's U.S. Expansion: A Bold Move in Spend Control

Perk Aims for U.S. Growth: Will It Pay Off? Amidst the cacophony of market chatter, Perk's announcement to bring its spend platform stateside is echoing louder than usual. This move is not just another step in its expansion but rather a leap considering the competition and market needs. In Europe, where they've already captured a chunk of the market with their Travel and...

Orthopedic Expert Highlighting Midwest Pain Access Gaps

Over in the vast sprawl of rolling plains and prairie winds, folks in the Upper Midwest are grappling with an ironic reality. As technological advancements blaze trails, people suffering from vertebrogenic pain are finding themselves up against a wall of limited access to specialized care. We’ve got Dr. James T. Brunz, the man of the hour, one of only about 15 Intracept...

G-STAR & Wu-Tang Clan Unleash Denim Fusion

Denim and Old-School Beats: A Fresh Partnership Just when you think fashion collaborations have run their course, along comes something worth the buzz. This fall, G-STAR, the edgy Dutch denim frontrunner, and the legendary hip-hop collective of Wu-Tang Clan are shaking up the apparel scene, blending raw denim with raw rap. It's a multi-year collaboration that doesn't slap...

CSS Revamps Identity, Emphasizing Senior Living Tech

CSS Takes a Bold Step with a Fresh Brand Identity Every now and then, you see a company shake off the old coat and put on a polished new one. That's what CSS is doing with its updated brand, staking its claim as a heavyweight tech player in the senior living sector. No small feat, given the challenges stacked against these aging communities—tasked with keeping...

Inovonics Duress Card Enhances Safety for K-12 and Beyond

A New Dawn for Safety in Schools and More It's about time we talk about something more substantial than just beefing up security cameras or tightening door locks. Real-world problems require nimble solutions, and that's where Status Solutions steps in with the Inovonics Duress Card. It's not just another gadget; it's a lightweight, wrist-mounted lifeline designed to say,...

Lumicell Expands LumiSystem in Breast Cancer Surgery

Innovation in Breast Cancer Surgery: A Real-World Game Changer? You’ve got your flashlight guiding a scared child through the dark, and in the healthcare world, Lumicell is promising to do just that for surgeons navigating the tricky maze of breast cancer surgery. Their LumiSystem is making waves in breast-conserving surgery—new kid on the block with a real chance at...

MasterBrand's 2027 Kitchen Trends: Embrace Warmth

Wood Finishes and the Warm Embrace Alright folks, let's cut through the fluff and get to the heart of the matter: wood finishes are making a roaring comeback in 2027 kitchens. And it's not just some passing phase, we're talking a comprehensive shift toward warmer and more natural kitchen designs. MasterBrand, Inc. isn't just throwing darts at a board here. They surveyed a...

FC2 Condom Educates NYC on Health and Wellness

Union Square Becomes a Hub of Interactivity The heart of NYC pulsed with purpose as FC2 Female Condom set up shop in Union Square, using the iconic location as a stage for a different kind of celebration. Clear Future, the manufacturer behind FC2, marked Global Female Condom Day with an event unlike any other. It wasn't just about the product—it was a call to educate...

Citrine Finalizes Sale of Illinois Senior Living Asset

Citrine's Strategic Exit from River Glen Every now and then, you see a company pull off something that makes you nod and say, "That was smart." Citrine Investment Group's sale of River Glen of St. Charles fits that bill. For those keeping tabs, this wasn't some quick flip—Citrine worked on the rock for a good while before cashing in. They secured River Glen back in...

BMAP Expands: Bridging Borders in Legal Advocacy

Breaking Down BMAP's Unique Approach Just when you thought you've seen it all, along comes LMU Loyola Law School swinging the doors wide open with their Binational Migrant Advocacy Project, or as we’re affectionately calling it, BMAP. It's a mouthful, sure, but ain't it something? This project isn't just another feather in academia's cap—it's a relentless counterpunch...